New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
16:38 EDTKITEKite Pharma announces positive phase 1-2a results, sees 92% objective response
Kite Pharma announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor, or CAR, T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute, or NCI, demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory Diffuse Large B-cell Lymphomr, or DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from 9 to 22 months. "We are greatly encouraged by the strong results we have seen from our joint lead clinical program with the NCI," commented Arie Belldegrun, Kite's president and CEO. "Based on this substantial progress, Kite plans to file an IND in Q4 of this year to initiate a Phase 1-2 single-arm multicenter clinical trial of KTE-C19 in patients with DLBCL who have failed two or more lines of therapy. We are excited to advance this promising therapy and anticipate commencing patient enrollment in our DLBCL clinical trial in the first half of 2015."
News For KITE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
08:09 EDTKITEKite Pharma price target raised to $71 from $45 at Stifel
Subscribe for More Information
December 11, 2014
07:59 EDTKITEKite Pharma 3.485M share Secondary priced at $54.00
Subscribe for More Information
December 9, 2014
16:08 EDTKITEKite Pharma files to sell 3M shares of common stock
Subscribe for More Information
December 7, 2014
14:10 EDTKITEAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use